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Abstract
Nanoparticles have shown considerable potential in many biological applications including drug delivery,
bio-imaging, and medical diagnostics. Specifically, the development of nanoparticle-based drug
formulations holds opportunities to improve the dissolution rate and oral availability of poorly watersoluble drugs. The goal of this project is to improve oral bioavailability of a small molecule drug (“G-1”)
through the formation of nanoparticles using the flash nanoprecipitation (FNP) process. Interestingly,
“G-1” formed ~80 nm particles that are electrostatically stabilized without the use of stabilizing polymers
and concentration as high as 160 mg/mL of “G-1” formed nanoparticles. Additionally, trehalose was
found to be an effective cryoprotectant for lyophilization of “G-1” nanoparticles suspension into stable
dried powders. Unexpectedly, the release kinetics of “G-1” in its free powder form exhibit rapid dissolution
rate in the modified biorelevant media (FaSSIF with 1.5% Tween 20). Further formulations with “G-1” were
conducted to generate ~300 nm particles with PS-b-PEG as stabilizing polymer. Through the use of a
tangential flow filtration (TFF) system, drug loading (wt%) of the lyophilized “G-1” nanoparticles were
increased by nearly 2-fold (30.5% versus 16.7%). These lyophilized nanoparticles were introduced to
Genentech’s in vivo and in vitro studies and have provided more insight in the bioavailability and
pharmacokinetics properties of this drug.
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Introduction
Nanotechnology offers substantial potential to revolutionize the drug delivery system. In
the last few decades, there has been tremendous progress in the development of therapeutic
nanoparticles.1 Size of nanoparticles range from 1 to 100 nm and these dimensions allows
the particles to interact with the biological systems in interesting ways.2 Several advantages
of nanoparticles include drug targeting to specific sites, the ability to cross biological
barriers, protection of the drug from degradation, and prolonged circulation times.3 In
addition, nanoparticles can be used for various route of drug administration such as oral,
ocular, and parenteral.4 These advantages of nanoparticles provide for promotion in drug
bioavailability and reduction in toxicity.
Flash Nanoprecipitation (FNP) is a technique used to construct drug-loaded polymeric
nanoparticles. In the technique of FNP, hydrophobic molecules and polymer are dissolved
in an organic solvent and rapidly mixed with the aqueous antisolvent. Upon rapid mixing
of the organic solvent and antisolvent, a condition of high supersaturation is attained which
leads to the nucleation and growth of particles. The block copolymer stabilized the surface
of the particle and arrest particle growth, resulting in precipitation of specific size
distribution of nanoparticles.5 Most importantly, FNP is an inexpensive and scalable
process that can generate stable nanoparticles with high drug loading and encapsulation
efficiency.6

Figure 1. Schematic representation of the Flash Nanoprecipitation process in a Confined
Impingement Jets mixer.7
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In FNP, mixing of organic solvent and antisolvent occurs in a confined mixing chamber
which can vary in geometry and size. In a Confined Impingement Jets (CIJ) mixer, the
organic solute and stabilizing polymer are dissolved in the organic stream. The organic
stream and the antisolvent stream collide each other at equal ratio of solvent to anti-solvent
(Figure 1).7 Higher supersaturations levels are limited through the use of CIJ. The MultiInlet Vortex Mixer (MIVM) design allows unequal ratio of solvent to anti-solvent mixing
which overcomes the limitation of the CIJ (Figure 2).8 Moreover, the CIJ has a two-inlet
design compared to the MIVM which has a four-inlet design that allows additional streams
of MQ water and increase supersaturation in the rapid mixing process.9,10 The additional
volume of water in the mixing process, decrease the solubility of the drug and result in
higher precipitation of nanoparticles. Figure 2 shows the arrangement of the four inlet
streams on the MIVM and an example stream composition for FNP.

Figure 2. Schematic representation of the Flash Nanoprecipitation process in the MultiInlet Vortex Mixer.8
It is estimated that 40% of active ingredients developed in pharmaceutical industry are
poorly water-soluble drugs.11 Oral drug delivery is the most convenient and preferred route
of administration based on low cost-effectiveness and high patient compliance.12
Administration of poorly-water soluble drugs provided the motivation for oral delivery
through nanoparticle-based therapeutics.13 Hydrophobic small molecule drugs are difficult
to absorb in the body due to poor water solubility and low dissolution rate in water.
Formulation of a poorly water-soluble compound using a nanoparticle approach can
enhance dissolution rate, drug solubility, and bioavailability.14 In comparison of
nanoparticles to conventional crude suspension, nanoparticles can minimize variation in
bioavailability of fed vs. fasted state.15 In addition, many poorly water-soluble molecules
are not dose proportional. Nanoparticle formulations of these molecules can improve or
implement dose proportionality.16 Moreover, drug nanoparticles have higher surface area
and surface interaction than particulates greater than 1 micron. The increased surface area
2

of nano-size particles can enhance dissolution rate and maximize the amount of drug
absorbed at the duodenal–jejunal area of the gastrointestinal tract.17 However, the
enormous increase in surface area can cause nanoparticles to aggregate or agglomerate into
a more thermodynamic stable state. For that reason, addition of stabilizing polymer is
needed to dampen or sensitize the surface energy of the nanoparticles through steric and/or
ionic interaction.18
In formulating nanoparticles for oral delivery of small molecule drug, a weakly
hydrophobic Genentech drug named “G-1” is used for nanoparticle formulation. “G-1” has
a log P of 6.18 and pKa of 4.3. The chemical structure of the drug has two notable functional
groups: carboxylic acid and indazole. The carboxylic acid can be deprotonated with a base
to generate carboxylate anion for nanoparticle formation. Various excipients such as
Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS), Hydroxypropyl
Methylcellulose E3 (HPMC E3), polyethylene glycol (PEG), polyvinyl alcohol (PVA),
Vitamin E TPGS and polystyrene-b-poly(ethylene glycol) (PS-b-PEG) were tested as
stabilizing polymer to encapsulate “G-1” into nanoparticles. Numerous nanoparticle
formulations are investigated through the FNP process via CIJ and MIVM. These
formulations include changes in drug concentration, percent of drug, percent of stabilizing
polymer, type of stabilizing polymer, equivalents of base, pH of antisolvent, choice of
organic solvent, volume of organic and antisolvents.
The goal of this capstone project is to improve the oral bioavailability of a small molecule
hydrophobic drug (“G-1”) by formation of nanoparticles through the FNP process. The
objective is to formulate nanoparticles of different sizes suitable for oral delivery and
process nanoparticles into dried powder form which can demonstrate re-dispersibility.
HPMCAS is a widely used polymer for spray-dried dispersion and hot melt extrusion in
the pharmaceutical industry.19,20 HPMCAS can enhance the solubility and increase
bioavailability of poorly soluble active pharmaceutical ingredients. Genentech generated
amorphous solid dispersion of “G-1” with HPMCAS by spray drying.21 The drug
dissociates from the HPMCAS polymer in vivo and precipitate to form nanoparticle in situ.
In this work, the usage of HPMCAS as a stabilizing polymer to encapsulate “G-1” into
nanoparticles was investigated for comparison to Genentech’s spray-dried dispersion of
“G-1” with HPMCAS. Formulation of different size nanoparticles can provide sizedependent dissolution profile and better understanding in the pharmacokinetics of this
drug. Nanoparticles in dry stable form are desirable for transportation and long-term
storage. Cryoprotectants are added into the nanoparticle suspensions before lyophilization
to stabilized against aggregation during freezing.22 Testing of various selection of
cryoprotectant is vital for re-dispersion of dried powders into nanometer-sized particles
when placed in water or an alternative water-based environment. It is critical that these
dried powders are capable of re-dispersing into non-aggregated/non-agglomerated
nanoparticulate dispersion for the development of solid dosage form.23 The re-dispersed
nanoparticles will be screened for their end application criteria: size, polydispersity index
(PDI), and stability. Formulations are optimized based on the re-dispersity of the
nanoparticles. Samples of the final formulations are sent to Genentech for dissolution
testing and pharmacokinetic studies.
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Materials and Method
Materials
Affinisol HPMC-AS 126 G (>94% purity), Affinisol HPMC-AS 716 G (>94% purity),
Affinisol HPMC-AS 912 G (>94% purity), and Methocel E3 Premium LV Hydroxypropyl
Methylcellulose (HPMC E3) were purchased from Dow Chemicals. Tetrahydrofuran
(HPLC grade, 99.9%), methanol (HPLC grade, 99.9% purity), dimethyl sulfoxide (HPLC
grade, 99.9% purity), acetone (HPLC grade, 99.9% purity), Tween 80, Tween 20, and
sodium hydroxide pellets were purchased from Fisher Chemicals. Phosphate buffered
saline (10X) was purchased from Lonza. Hydrochloric acid and potassium chloride were
purchased from EMD Millipore. Pluronic F-127 was purchased from BASF Corporation.
Vitamin E-TPGS were purchased from Peboc. Hydroxypropyl-β-cyclodextrin were
purchased from Acros Organics. Poly(vinyl alcohol), polyethylene glycol and mannitol
(>98% purity) were purchased from Sigma Aldrich. Fasted-state simulated intestinal fluid
(FaSSIF) and fedstate simulated intestinal fluid (FeSSIF) were purchased from
Biorelevant.com. “G-1” was supplied by Genentech. Trehalose (>99% purity) was
purchased from Fluka. Poly(styrene)1.6kDa-block-poly(ethylene glycol)5kDa were purchased
from were purchased from Polymer Source Inc. DI (DI) water (18.2 MΩ·cm) was prepared
by a NANOpure Diamond UV ultrapure water system (Barnstead International, Dubuque,
IA).
Solubility Profile of “G-1” and HPMCAS-126
An excess of different organic solvent (methanol, tetrahydrofuran, dimethyl sulfoxide, and
acetone) was added separately to glass vials containing 15.0 mg of “G-1”. Solutions of
HPMCAS-126 in different organic solvent (methanol, tetrahydrofuran, dimethyl sulfoxide,
and ethanol) at a concentration of 20 mg/mL were prepared. Visual observation on the
solubility of “G-1” and HPMCAS-126 was conducted.
Precipitation and Solubility Studies of “G-1”
A solution of 1x PBS was prepared through a tenfold dilution with 10x PBS. “G-1” in
different organic solvent (methanol, tetrahydrofuran, and dimethyl sulfoxide) at a
concentration of 20 mg/mL were generated and were mixed with antisolvent (water or
PBS) in a final volume of 1.5 mL at different percentages, ranging from 90 % of the organic
solvent and 10 % of antisolvent to 10 % of the organic solvent and 90 % of the antisolvent.
The mixed solvent with precipitation were centrifuged at 14800 rpm for 15 minutes. A
sample was aliquot out of the supernatant of the solution. The sample was diluted up to
1000-fold and analyzed by UV-vis spectrometry.
Preparation of “G-1” Nanoparticles.
“G-1” with HPMCAS
A pellet of sodium hydroxide was added to methanol to prepare a stock solution at a
concentration of 10 mg/mL through sonication. A stock solution of HPMCAS-126 in
methanol at a concentration of 20 mg/mL with 0.50 and 0.75 equivalents of sodium
hydroxide were prepared. A stock solution of “G-1”in methanol at a concentration of 20
mg/mL were prepared. Attempts to generated “G-1” nanoparticles with HPMCAS were
prepared via CIJ and MIVM. The organic stream consisted of “G-1”and HPMCAS-126
4

dissolved in 0.5 mL of methanol were prepared with the stock solutions. The rapid mixing
of organic stream and antisolvent DI water streams was conducted via CIJ and MIVM. The
mixture was subsequently dispersed in 9.0 mL (CIJ) or 6.0 mL (MIVM) of DI water which
decrease the organic solvent to 10 vol%.
“G-1” with various excipients (HPMC E3, F-127, PVA, Tween 80, and Vitamin E TPGS)
“G-1” nanoparticles with various excipients to act as stabilizing polymers were prepared
via MIVM. The antisolvent 10 mM HCl streams were prepared by dilution of 1M HCl with
DI water. The three antisolvent stream consisted of 1.0 mL of 10 mM HCl or DI water
were rapidly mixed with the organic stream which consisted of “G-1” (20 mg/mL) and
stabilizing polymer (2 mg/mL) in 0.5 mL of methanol via MIVM. The mixture was
dispersed into a quench bath of DI water (6.0 mL), resulting in a final organic concentration
of 10 vol%.
“G-1” with no stabilizing polymers
“G-1” nanoparticles in suspension without stabilizing polymers were generated by FNP
using the four-stream MIVM. Different concentration of “G-1”in methanol (20 mg/mL, 40
mg/mL, 80 mg/mL, and 160 mg/mL) was prepared with different equivalents of sodium
hydroxide (0.00 eq, 0.05 eq, 0.10 eq, 0.20 eq, and 0.40 eq) for the organic stream (1.0 mL)
in the MIVM. Rapid mixing of the organic stream and the three antisolvent DI water stream
(1.0 mL each) was conducted via MIVM. The suspension mixture was dispersed as
previously described.
“G-1” with PS-b-PEG
PS-b-PEG “G-1” nanoparticles in suspension were generated by FNP using the four-stream
MIVM. Different amount of % drug (25, 50, 75% and etc.) and % PS-b-PEG (75, 50, 25%
and etc.) were dissolved in 0.5 mL of methanol (total mass concentration: 40 mg/mL or 20
mg/mL). The rapid mixing of the organic stream (0.5 mL of methanol) and antisolvent
stream (4.5 mL of DI water) resulted in a mixture with a final organic concentration of 10
vol% which was dispersed into a 20 mL vial.
“G-1” with increased drug loading (wt%)
“G-1” nanoparticles (80 mg/mL of “G-1” with 0.05 eq of NaOH) in suspension were
generated as previously described. The rapid mixing of the organic stream (4.0 mL of
methanol) and antisolvent stream (12.0 mL of DI water) was conducted via MIVM. The
mixture was dispersed into a quench bath of DI water (24.0 mL), resulting in a final
organic concentration of 10 vol%. The nanoparticle suspension (40.0 mL) underwent
filtration using a MicroKros® Module (MWCO: 100 kD) and removed water (32.0 mL)
from solution, concentrating the nanoparticle suspension by 5-fold.
Nanoparticle Characterization
Nanoparticle size and PDI were assessed by dynamic light scattering using a Zetasizer
Nano-ZS at 25 °C with a detection angle of 173° in triplicate. To avoid multiple light
scattering, the samples were diluted 10-fold prior to DLS. The size is determined through
a series of light scattering correlation function. The PDI is obtained through the Taylor
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series expansion of the correlation function from the Malvern Nanosizer data analysis
software.
Nanoparticle Lyophilization
Nanoparticle suspensions were lyophilized into dry powders using a benchtop VirTis
Advantage without and with cryoprotectants (i.e. PVA, PEG, Trehalose, Mannitol, F-127,
and HPMC E3). 200 mg of cryoprotectant were added to 5 mL of nanoparticle solutions to
afford NP:cryoprotectant weight ratios of 1:5. The mixture solution were flash frozen in a
container of dry ice. The frozen samples were transferred to the freeze-dryer at -20 °C
under vacuum to remove the water and organic solvents from the nanoparticles. After 24
hours, dried powders were obtained and stored at -20 °C. Samples were re-disperse with 5
mL of DI water for DLS analysis.
“G-1” Solubility and Release Kinetics
FeSSIF (Fed State Simulated Intestinal Fluid) and FaSSIF (Fasted State Simulated
Intestinal Fluid) buffer consisted of different percentage of Tween 20 (0.5% and 1.5%)
were prepared. An excess of “G-1” powder was added to FeSSIF and FaSSIF buffer,
respectively, followed by a slow rotation on the Glas-Col rotator for 96 h to allow
maximum saturation of the drug in solution. The solution was aliquot into Amicon and Pall
filters to remove the undissolved drug from the solution. The solution was centrifuged at
5000 rcf for 10 minutes. The supernatant of the solution was analyzed by UV-vis
spectrometry. The concentration of “G-1” was calculated using a calibration curve with
known standard solution. In the dissolution testing procedures, approximately 5.0 mg of
“G-1” is added to 20.0 mL of FaSSIF with 1.5% Tween. Solution was aliquot into Pall
filters and the supernatant of the solution was analyzed by UV-Vis spectrometry at 15minute and 30-minute timepoint. The concentration of “G-1” at each time point was
calculated using a standard curve.
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Results and Discussion
Solubility Profile of “G-1” and HPMCAS
In the FNP process, the drug and the stabilizing polymer are dissolved in the organic
solvent and rapidly mixed with the antisolvent to form nanoparticles in suspension. Thus,
several common organic solvents (e.g., methanol, THF, DMSO and acetone) were screened
as candidates for the FNP process. Solubility of “G-1” and HPMCAS in the organic
solvents were qualitative measured by visual representations. The solubility of “G-1” was
tested in methanol, THF, DMSO, and acetone. “G-1” is found to be soluble in all four
solvents. The solubility of HPMCAS was tested in acetone, ethanol, methanol, and THF.
HMPCAS is found to be soluble in all solvents except ethanol (Table 1). Methanol, THF,
DMSO, and acetone were selected as the organic solvent for the FNP process as “G-1” and
HPMCAS were both soluble in those solvents.
Table 1. Solubility profiling of “G-1” and HPMCAS in different solvents.
Methanol
THF
DMSO
Acetone
“G-1”
Soluble
Soluble
Soluble
Soluble
HPMCAS
Soluble
Soluble
Soluble
Soluble

Ethanol
N/A
Insoluble

“G-1” Detection by UV-Vis
Ultraviolet–visible spectroscopy (UV-Vis) can be used to detect the presence of “G-1” and
determine the concentration of “G-1” in an organic solvent. UV-Vis was used to analyzed
“G-1” in methanol, THF, DMSO and acetone, respectively. Analysis of “G-1” in methanol
(50 μg/mL) by UV-Vis gave corresponding absorption peaks at the wavelength of 255 nm
and 305 nm (Figure 3). Absorption spectrum of the blank methanol solution (blue line)
and “G-1” methanol solution (orange line) is shown in Figure 3. “G-1” in methanol
absorbed most strongly at 255 nm and 305 nm wavelength, creating two maxima in the
absorption spectrum. In addition, “G-1” can be detected in THF and DMSO by UV-Vis as
absorption spectrum can be generated from the drug in either solvents. However, UV-Vis
cannot be used for the detection of “G-1” in acetone due to the overlap absorption peak of
blank acetone and the absorption peak of the drug at 305 nm.
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Figure 3. “G-1” dissolved in methanol and its corresponding absorption peak at 305 nm
shown from the UV-VIS.
Precipitation and Solubility Studies of “G-1”
High “G-1” supersaturation must be achieved for formation of nanoparticles when the
organic stream and antisolvent stream collide in FNP. For that reason, precipitation and
solubility studies of “G-1” in methanol, THF, and DMSO were performed to investigate
potential organic solvent for the FNP process. “G-1” in different organic solvents
(methanol, THF, and DMSO) were separately mixed with antisolvent deionized (DI) water
at different percentage to generate three series of mixtures (Series A, Series B, and Series
C) and were observed for precipitation (Table 2). Each series of mixture were prepared
with different organic solvents: Series A (methanol), Series B (THF), and Series C
(DMSO). In series B, precipitation of the drug occurs at 40% THF and 60% DI water. In
series A and C, precipitation of the drug occurs at 60% methanol or DMSO and 40% DI
water. Calibration curves were constructed in methanol by preparing a series of
concentrations of the drug (1, 5, 10, 25, 50, 75 μg/mL). Solubility curves of “G-1” were
generated from four final mixed solvents (Figure 4). Solubility curve of “G-1” in four final
mixed solvents (methanol with DI water, methanol with PBS, THF with DI water, and
DMSO with DI water) are shown in Figure 4. The replacement of DI water with PBS was
expected to decrease the solubility of “G-1” in methanol. However, “G-1” in methanol with
PBS had a higher solubility curve compare to “G-1” in methanol with DI water. Similarly,
the solubility curve of “G-1” in THF with DI water was higher than the solubility curve of
“G-1” in methanol with DI water. The solubility curve of “G-1” in DMSO with DI water
displayed a similar trend to the solubility curve of “G-1” in methanol with DI water.
8

Although, supernatant of the solution and the precipitation of “G-1” at 20% DMSO could
not be separated through centrifugation. Most importantly, solubility of “G-1” is lowest at
20% methanol. In other words, vast amount of “G-1” precipitate at 20% methanol and high
supersaturation is desired for the FNP process. Thus, methanol was selected for the organic
stream in the FNP process due to the low solubility of “G-1” in the final mixed solvent.
Table 2. Precipitation studies of “G-1” in different solvents. P = Precipitation and NP =
No Precipitation.
Organic
Antisolvent %
Series A
Series B
Series C
Solvent %
Methanol:Water
THF:Water
DMSO:Water
100 %
90 %
80 %
70 %
60 %
50 %
40 %
30 %
20 %
10 %
0%

0%
10 %
20 %
30 %
40 %
50 %
60 %
70 %
80 %
90 %
100 %

NP
NP
NP
NP
P
P
P
P
P
P
P

NP
NP
NP
NP
NP
NP
P
P
P
P
P

NP
NP
NP
NP
P
P
P
P
P
P
P

10000

Solubility, μg/mL

1000

DMSO

100

MeOH
MeOH PBS

10

THF

1
0

10

20

30
40
50
60
70
Volume % Organic Solvent
Figure 4. Solubility of “G-1” in mixtures of organic solvents to antisolvent in different
percentages (Methanol:Water, Methanol:PBS, DMSO:Water, and THF:Water).
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“G-1” Nanoparticles
HPMCAS is a cellulosic derivative polymer with acetyl and succinyl substitutions along
its backbone (Figure 5). In addition, HPMCAS is a polymer that can provide stable
amorphous solids dispersions with poorly soluble drugs. Hypothetically, the succinate
groups on HPMCAS can be deprotonated with a base which allows the anionic succinate
group to act as the surface stabilizing polymer to encapsulate “G-1” into nanoparticles.
Various formulations consisted of different percentage of drug and HPMCAS-126 in 0.50
and 0.75 equivalents of sodium hydroxide was conducted through via CIJ and MIVM
(Table 3). The formulations that underwent the FNP process in an attempt to form “G-1”
nanoparticles with HPMCAS are listed in Table 3. Initial formulations were conducted via
CIJ and later formulations were conducted via MIVM, in order to increase precipitation of
“G-1” nanoparticles by introducing higher volume of DI water during the FNP process to
decrease the solubility of “G-1” in methanol. Several variables of the formulations were
modified such as increasing equivalents of sodium hydroxide and changing the percentage
of the drug and HPMCAS-126. attempts to form “G-1” nanoparticles with HPMCAS. For
all formulations tested in Table 3, no formulations were successful in forming “G-1”
nanoparticles with HPMCAS-126. It is hypothesized that “G-1” form electrostatically
stabilized nanoparticles which have an anionic surface that repels the anionic succinate
groups of HPMCAS, preventing HPMCAS to act as a stabilizing polymer with the drug to
form nanoparticles.

Figure 5. Chemical structure of Hydroxypropyl Methylcellulose Acetate Succinate.
To investigate whether “G-1” and its free acid form can participate in nanoparticle
formation, a series of formulation consisted of “G-1” and various excipients (HPMC E3,
F-127, PVA, Tween 80, and Vitamin E TPGS) dissolved in methanol (1.0 mL) were rapidly
mixed with 10 mM HCl or DI water through the FNP process via MIVM (Table 4). The
series of formulations were observed for nanoparticle formation and aggregation in the
quench bath. The list of different formulations tested through the FNP process in an attempt
to form “G-1” nanoparticles with a stabilizing polymer are shown in Table 4. Through
visual observation, no aggregation was found in the formulations with DI water as the
antisolvent. In addition, aggregation was found in all formulations with 10 mM HCl as the
antisolvent except when F-127 was used as stabilizing polymer. In particular, three
formulations resulted in forming well defined nanoparticles with “G-1” (Figure 6). Particle
size distribution of the three successful nanoparticle formulation (PVA in DI water, vitamin
E TPGS in DI water, and F-127 in 10 mM HCl) are shown in Figure 6. The size of the
nanoparticles produced from these formulations were less than 200 nm with narrow size
10

distribution (PDI > 0.25). “G-1” nanoparticles can be formulated with specific stabilizing
polymer and antisolvents.
Table 3. Formulations to prepare "G-1" nanoparticles with HPMCAS.a
Type of
Total mass
Sodium
% Drug % HPMCASNanoparticle
Mixer concentration
Hydroxide
126
formation with
Equivalents to
HPMCAS-126
HPMCAS
CIJ
20 mg/mL
0.50 eq
100%
0%
No
CIJ
20 mg/mL
0.50 eq
75%
25%
No
CIJ
20 mg/mL
0.50 eq
50%
50%
No
MIVM
20 mg/mL
0.50 eq
100%
0%
No
MIVM
20 mg/mL
0.50 eq
90%
10%
No
MIVM
20 mg/mL
0.50 eq
50%
50%
No
MIVM
20 mg/mL
0.75 eq
90%
10%
No
MIVM
20 mg/mL
0.75 eq
50%
50%
No
a
Methanol (0.5 mL) was used as the organic stream.
Table 4. Formulations consisted of “G-1” with different stabilizing polymers in
combination with 10 mM HCl or DI water as antisolvent.a
“G-1”
Stabilizing
Stabilizing
Antisolvent
NP
Concentration
Polymer
Polymers
Formation
Concentration
(Size >200 nm)
(PDI >0.25)
20 mg/mL
2 mg/mL
HPMC E3
10 mM HCl
No
20 mg/mL
2 mg/mL
F-127
10 mM HCl
Yes
20 mg/mL
2 mg/mL
PVA
10 mM HCl
No
20 mg/mL
2 mg/mL
Tween 80
10 mM HCl
No
20 mg/mL
2 mg/mL
Vitamin E TPGS 10 mM HCl
No
20 mg/mL
2 mg/mL
HPMC E3
DI water
No
20 mg/mL
2 mg/mL
F-127
DI water
No
20 mg/mL
2 mg/mL
PVA
DI water
Yes
20 mg/mL
2 mg/mL
Tween 80
DI water
No
20 mg/mL
2 mg/mL
Vitamin E TPGS
DI water
Yes
a
Methanol (1.0 mL) was used as the organic stream.
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Figure 6. Particle size distribution of “G-1” nanoparticles with different stabilizing
polymer and antisolvents.
Table 5. Formulations consisted of “G-1” with different equivalents of sodium
hydroxide.a
“G-1”
Sodium
Antisolvent
NP
Size
Size
Concentration
Hydroxide
Formation
Distribution
Equivalents
(PDI)
(eq)
20 mg/mL
0.05
DI water
Yes
80
0.23

a

20 mg/mL

0.10

DI water

Yes

60

0.23

20 mg/mL

0.20

DI water

Yes

50

0.28

20 mg/mL

0.40

DI water

Yes

40

0.26

Methanol (1.0 mL) was used as the organic stream.
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Figure 7. Particle size distribution of “G-1” nanoparticles formed under different
equivalents (0.00 eq, 0.05 eq, 0.10 eq, 0.20 eq and 0.40 eq) of NaOH.
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Figure 8. Particle size distribution of “G-1” nanoparticles formed with 160 mg/mL of
“G-1” and 0.20 eq of NaOH.
13

Table 6. Formulations consisted of “G-1” with various grade of HPMCAS in different
equivalents of sodium hydroxide.a
“G-1”
Sodium
Stabilizing
Stabilizing Antisolvent
NP
Concentration Hydroxide
Polymer
Polymers
Formation
Equivalents Concentration
(eq)
40 mg/mL
0.00
20 mg/mL
HPMCASDI water
No
126
40 mg/mL
0.50
20 mg/mL
HPMCASDI water
No
126
40 mg/mL
0.75
20 mg/mL
HPMCASDI water
No
126
40 mg/mL
0.00
20 mg/mL
HPMCASDI water
No
712
40 mg/mL
0.50
20 mg/mL
HPMCASDI water
No
712
40 mg/mL
0.75
20 mg/mL
HPMCASDI water
No
712
40 mg/mL
0.00
20 mg/mL
HPMCASDI water
No
912
40 mg/mL
0.50
20 mg/mL
HPMCASDI water
No
912
40 mg/mL
0.75
20 mg/mL
HPMCASDI water
No
912
a
Methanol (1.0 mL) was used as the organic stream.
“G-1” (20 mg/mL) with different equivalents of sodium hydroxide (0.00 eq, 0.05 eq, 0.10
eq, 0.20 eq, and 0.40 eq) generate nanoparticles through FNP via MIVM (Table 5). The
list of different formulations tested through the FNP process in an attempt to form “G-1”
nanoparticles with different equivalents of sodium hydroxide are tabulated in Table 5.
Particle size distribution of “G-1” nanoparticles formulated with different equivalents of
sodium hydroxide were measured by DLS (Figure 7). Figure 7 shows an inverse
correlation between the size of “G-1” nanoparticles and the equivalents of sodium
hydroxide. The size of “G-1” nanoparticles decrease as higher equivalents of sodium
hydroxide was used in the formulation for the FNP process. The size of nanoparticles can
be controlled from ~40 to ~80 nm based on the equivalent amount of sodium hydroxide
used in the formulation process. The formulation was optimized for further downstream
processing, higher concentrations of “G-1” was tested for nanoparticle formation. “G-1” at
concentrations of 40 mg/mL, 80 mg/mL, and 160 mg/mL formed nanoparticles. Particle
size distribution of “G-1” nanoparticles formulated with 160 mg/mL of “G-1” and 0.20 eq
of NaOH was measured by DLS (Figure 8). “G-1” at a concentration of 160 mg/mL were
able to form nanoparticles with sizes around ~100 nm, and slightly narrow size distribution
(PDI 0.31). In addition, various grade of HPMCAS (HPMCAS-126, HPMCAS-712, and
HPMCAS-912) in different equivalents of sodium hydroxide (0.00 eq, 0.50 eq, 0.75 eq)
with “G-1” (40 mg/mL) was formulated for nanoparticle formation (Table 6). “G-1” did
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not form nanoparticle with the different grades of HPMCAS and aggregation was visually
observed for all formulations tested. In summary, HPMCAS failed to act as a stabilizing
polymer with “G-1” to form nanoparticles.
Freeze-drying of “G-1” Nanoparticles and Redispersion
Lyophilization is a process widely used in pharmaceuticals to dry and improve the stability
of pharmaceutical products.24 “G-1” with 0.05 equivalents and 0.20 equivalents of sodium
hydroxide generated nanoparticles that were desirable for lyophilization. Formulations for
these nanoparticles were pursued for further testing with various stabilizing polymer and
cryoprotectants for freeze-drying. “G-1” with 0.05 equivalents of sodium hydroxide
nanoparticles and “G-1” with 0.20 equivalents of sodium hydroxide nanoparticles with
different stabilizing polymers were lyophilized without any cryoprotectants (Table 7).
Formulations with different equivalents of sodium hydroxide and stabilizing polymers
conducted through the FNP process via MIVM are listed in Table 7. The dry powder form
of “G-1” were re-dispersed with DI water and analyzed through DLS. The “G-1” powder
failed to re-dispersed back to nanoscale and form aggregation upon re-dispersion with DI
water.
The process of freeze-drying can induce mechanical stress that could destabilize colloidal
suspension of nanoparticles and cause nanoparticles to aggregate. For that reason,
cryoprotectants are added to the nanoparticle suspension before freezing to protect the
nanoparticles from freezing stress and preserve re-dispersibility of the nanoparticles.25
HPMC E3 is a water-soluble HPMC polymer and serves as a cryoprotectant.26 Three
formulations were tested with HPMC E3 to determine if HPMC E3 is an effective
cryoprotectant for “G-1” nanoparticles. “G-1” with different equivalents of sodium
hydroxide (0.00 eq, 0.05 eq, and 0.20 eq) nanoparticles with HPMC E3 were lyophilized
(Table 8). The formulations tested with HPMC E3 as cryoprotectant were conducted
through the FNP process via MIVM are listed in Table 8. The dry powder form of “G-1”
were re-dispersed with DI water and analyzed through DLS. In conclusion, HPMC E3 was
not an effective cryoprotectant and failed to form powder that can re-disperse back to
nanoscale.
“G-1” nanoparticles with 0.05 equivalents of sodium hydroxide and “G-1” nanoparticles
with 0.20 equivalents of sodium hydroxide were lyophilized into dried powder form. Seven
excipients (PVA, PEG, trehalose, Mannitol, F-127, cyclodextrin, and propylvinylpyridone)
were tested to determine which excipient is the most effective cryoprotectant for redispersion of freeze-dried “G-1” powder. The lyophilized powder of “G-1” nanoparticles
with good redispersity retains similar size and size distribution as nanoparticles before
lyophilization. Freeze dried powder of “G-1” with 0.05 equivalents of sodium hydroxide
re-dispersed into nanoparticles in DI water when PEG or trehalose is selected as the
cryoprotectant for lyophilization (Figure 9). Particle size distribution of the re-dispersed
“G-1” with 0.05 equivalents of sodium hydroxide nanoparticles with trehalose and “G-1”
with 0.05 equivalents of sodium hydroxide nanoparticles with PEG are shown in Figure
9. These nanoparticles redispersed back to nanoscale when PEG or trehalose is used as a
cryoprotectant. Trehalose was the most effective cryoprotectant in redispersion of “G-1”
nanoparticles formulated with 0.05 equivalents of sodium hydroxide as size and size
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distribution were similar to nanoparticles before lyophilization. In addition, freeze dried
powder of “G-1” with 0.20 equivalents of sodium hydroxide re-dispersed into
nanoparticles in DI water when PEG is selected as the cryoprotectant for lyophilization
(Figure 10). The particle size distribution of re-dispersed “G-1” with 0.20 equivalents of
sodium hydroxide nanoparticles with PEG are shown in Figure 10. The dried powder did
not re-disperse back to nanoscale when trehalose was used as a cryoprotectant.
Table 7. Formulations consisted of “G-1” with and without stabilizing polymers in
different sodium hydroxide equivalents.a
“G-1”
Sodium
Stabilizing
Stabilizing Antisolvent Dispersion
Concentration Hydroxide
Polymer
Polymers
of NP
Equivalents Concentration
(eq)
80 mg/mL
0.05
N/A
N/A
DI water
No
80 mg/mL
0.20
N/A
N/A
DI water
No
80 mg/mL
0.05
2 mg/mL
PVA
DI water
No
80 mg/mL
0.20
2 mg/mL
PVA
DI water
No
80 mg/mL
0.05
2 mg/mL
Vitamin E
DI water
No
TPGS
80 mg/mL
0.20
2 mg/mL
Vitamin E
DI water
No
TPGS
a
Methanol (1 mL) was used as the organic stream.
Table 8. Formulations consisted of “G-1” with HPMC E3 in different sodium hydroxide
equivalents.a
“G-1”
Sodium
Stabilizing
Stabilizing Antisolvent Dispersion
Concentration Hydroxide
Polymer
Polymers
of NP
Equivalents Concentration
(eq)
20 mg/mL
0.00
20 mg/mL
HPMC E3
DI water
No
20 mg/mL
0.05
20 mg/mL
HPMC E3
DI water
No
20 mg/mL
0.20
20 mg/mL
HPMC E3
DI water
No
a
Methanol (1 mL) was used as the organic stream.
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Figure 9. Particle size distribution of “G-1” with 0.05 equivalents of sodium hydroxide
nanoparticles before and after lyophilization with selected cryoprotectants (PEG and
trehalose).
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Figure 10. Particle size distribution of “G-1” with 0.20 equivalents of sodium hydroxide
nanoparticles before and after lyophilization with PEG as the selected cryoprotectant.
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Trehalose was the most effective cryoprotectant for lyophilization of “G-1” nanoparticles.
The average size of the re-disperse “G-1” nanoparticles increased by 10 nm with similar
PDI. Different mass ratios of trehalose to nanoparticles (5:1, 4:1, 3:1, 2:1, and 1:1) was
tested to determine the minimum amount of trehalose required to behave as a
cryoprotectant. The re-dispersed “G-1” nanoparticles with different mass equivalents of
trehalose (5:1, 4:1, and 3:1) was analyzed through DLS (Figure 11). Particle size
distribution of different mass equivalents of trehalose to “G-1” nanoparticles (5:1, 4:1, and
3:1) are shown in Figure 11. High amount of aggregation was observed for formulations
with 2:1 and 1:1 ratio, and thus particle size distribution could not be analyzed by DLS.
The formulation (80 mg/mL of “G-1” with 0.05 equivalents of NaOH in MeOH) with 5
mass equivalents of trehalose was repeated and the nanosuspension was lyophilized. The
dried powder was sent to Genentech for pharmacokinetics studies. The results from
Genentech conclude that the “G-1” nanoparticles with trehalose have faster dissolution rate
than the nanoparticles formed in vivo from Genentech's spray dried dispersion.
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Figure 11. Particle size distribution of “G-1” nanoparticles with different amount of
trehalose.
Release Kinetics
“G-1” is insoluble in water (log P = 6.18). For oral delivery, rapid dissolution rate
(complete dissolution of drug in less than one hour) of the drug is desirable for high
bioavailability. A rapid dissolution rate of the drug results in high solubility of the drug in
a short amount of time. In this objective, solubility of “G-1” in biorelevant media was
measured to determine the released "G-1" concentration and supersaturation level of "G1". It is hypothesized that free “G-1” powder would have a slower dissolution rate than “G1” nanoparticles. Slower dissolution rate of free “G-1” powder result in lower solubility of
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“G-1” in solution compare to “G-1” nanoparticles. The release experiments were
performed on the free “G-1” powder to compare with the release kinetics of “G-1”
nanoparticles. In dissolution testing procedures, sink condition is described as a dissolution
system that has volume of solvent which is five to ten times greater than the volume of
solvent present in a saturated solution.27 In other words, a “sink” is required to prevent
saturation in a dissolution assay. In order to mimic the oral administration of “G-1”, FeSSIF
and FaSSIF were selected as biorelevant media for in vitro dissolution tests which stimulate
the physiological condition in the gastrointestinal tract. FeSSIF and FaSSIF contains
biological lipids such as sodium taurocholate and lecithin which can act as a lipid sink for
the drug. However, the undissolved nanoparticles cannot be separated from the large lipid
globules through centrifugation or filtration due to similar size of the nanoparticles and
lipid globules, thus an alternative media is necessary for the dissolution testing.
Tween 20 can be used to mimic biological lipids which can facilitate separation from the
undissolved nanoparticle. Most importantly, Tween 20 can act as a hydrophobic sink to
increase the solubility of “G-1” in FaSSIF and FeSSIF media.28 In preparation of the
modified biorelevant media, Tween 20 (0.5% and 1.5%) were added to FeSSIF and FaSSIF
buffers in substitution of the SIF powder which contains the biological lipids, sodium
taurocholate and lecithin. Four different dissolution media (FaSSIF with 0.5% Tween 20,
FaSSIF with 1.5% Tween 20, FeSSIF with 0.5% Tween 20, and FeSSIF 1.5% Tween 20)
were prepared and free “G-1” powder was added to each media to determine the maximum
saturation of the drug in solution and its sink conditions. The pH and concentration of “G1” in each dissolution media was measured by pH indicator and UV-Vis, respectively
(Table 9). Among the four different dissolution media, “G-1” in FaSSIF with 1.5% Tween
20 had the highest maximum saturation solubility (2504 μg/mL). FaSSIF with 1.5% Tween
20 was selected for dissolution testing of “G-1” with the sink condition at 250 μg/mL, ten
times below saturation limit.
Methods of separating undissolved “G-1” from dissolved “G-1” were investigated for the
dissolution test. Undissolved and dissolved “G-1” was separated by Amicon filter (made
of regenerated cellulose) and the concentration of “G-1” were measured. High levels of
adsorption to the filter membrane were observed. The concentration of filtered “G-1” was
substantially lower than the concentration of “G-1” before filtration as shown in Table 9.
Standard curve of “G-1” before filtration and after Pall filtration (made of modified
polyethersulfone) was generated (Figure 12). Minor adsorption to the filter membrane
were quantitatively observed. The concentration of “G-1” did not change dramatically
There are minimal differences between the two different standard curves of “G-1”: before
filtration (blue line) and after Pall filtration (orange line). In order to achieve the sink
condition of the dissolution test (250 μg/mL), 5.0 mg of “G-1” is added to 20.0 mL of
FaSSIF with 1.5% Tween. Dissolution testing of “G-1” in FaSSIF with 1.5% Tween 20
was performed and the concentration of “G-1” was measured by UV-Vis (Figure 13). In
addition, the maximum saturation solubility for the dissolution test (250 μg/mL) was
measured by UV-Vis and the absorbance value of the maximum saturation solubility is
1.52 au. In Figure 13, about >90% of the free “G-1” powder had dissolved in solution
within the first timepoint (15 minutes). Due to rapid dissolution of the free “G-1” powder,
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dissolution test for “G-1” nanoparticles were not tested as it would be difficult to
differentiate the differences in release kinetics between the free powder drug and the drug
nanoparticle.
Table 9. Measurements of pH, maximum saturation solubility, and maximum saturation
solubility in FaSSIF and FeSSIF solutions with different amounts of Tween 20 (0.5% or
1.5%)
Dissolution
pH
“G-1” Concentration
“G-1” Concentration
Media
(maximum saturation
after Amicon filter
solubility)
(maximum saturation
solubility)
FaSSIF in 0.5%
6.36
644 μg/mL
473 μg/mL
Tween 20
FaSSIF in 1.5%
6.17
2504 μg/mL
792 μg/mL
Tween 20
FeSSIF in 0.5%
5.00
292 μg/mL
147 μg/mL
Tween 20
FeSSIF in 1.5%
5.02
1226 μg/mL
412 μg/mL
Tween 20
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Figure 12. Standard curve of “G-1” before filtration and after Pall filtration.
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Figure 13. Release kinetic of “G-1” in FaSSIF with 1.5% Tween 20.
Increase Nanoparticle Size Formulation
Various formulations were investigated to increase the size of “G-1” nanoparticles for
comparison with Genentech’s spray-dried dispersion of “G-1” with HPMCAS which
precipitate and formed 200 to 800 nm particles in vivo. Formulation of different size
nanoparticles can provide more in-depth knowledge about the dissolution behavior and oral
absorption of “G-1”. Particle size is often related to the solubility of the drug. The decrease
in solubility of the drug result in larger particles due to the particles having less interaction
with the solvent.29 Hydrophobicity of the drug is increased when “G-1” is in its free acid
form which allow the polymer to stabilize the drug nanoparticle. By decreasing the
solubility and increasing the hydrophobicity of “G-1”, larger size nanoparticles can be
generated. Concentration of “G-1” in four different solutions was measured by UV-Vis:
HCl, KCl, HCl with KCl, and DI water (Table 10). Among the four solutions, “G-1” had
the lowest solubility in 10 mM HCl. “G-1” is insoluble in 10 mM HCl as concentration of
“G-1” in 10 mM HCl was below detection limit. 10 mM HCl was selected as the antisolvent
to completely protonate drug and reduce surface charge in the formation of nanoparticles.
Table 10. Solubility of “G-1” in HCl, KCl, HCl with KCl, and DI water.
Solution
“G-1” Concentration
10 mM HCl
150 mM KCl
10 mM HCl and 150 mM KCl
DI water

Below detection limit
4 μg/mL
2 μg/mL
37 μg/mL
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Formulation to generate ~200 to 300 nm particles from “G-1” were desired. The DLS
analysis of formulations to generate ~200 to 300 nm “G-1” nanoparticle is tabulated in
Table 11. For all formulations shown in Table 11, THF was selected for the organic stream
and 10 mM HCl was selected for the antisolvent stream in the FNP process. In addition,
all the formulations are conducted via MIVM and the nanoparticle suspension were
measured by DLS. Polystyrene-b-poly(ethylene glycol) (PS-b-PEG) is an amphiphilic
diblock copolymer which can stabilize hydrophobic drug nanoparticles formed by flash
nanoprecipitation (FNP).30 THF was selected for the organic stream in the FNP process
because PS-b-PEG is soluble in THF and not soluble in methanol. PS-b-PEG polymer were
able to form “G-1” nanoparticles, with sizes ranging from ~100 to ~500 nm, and narrow
size distribution, (PDI 0.07−0.22).
In entry #1 to #3, different percentage of drug (25.0, 50.0, and 75.0%) and PS-b-PEG (75.0,
50.0, and 25.0%) were formulated to generate PS-b-PEG nanoparticles. In entry #4,
formulation consisted of “G-1” without PS-b-PEG was conducted to investigate whether
PS-b-PEG is necessary for the formation of nanoparticles. “G-1” nanoparticles did not form
without PS-b-PEG and aggregations were visually observed. In entry #5, formulation
without the quench bath was conducted to observe whether the quench bath affect the
formation of nanoparticles. Particle size increased from 220 nm to 500 nm when quench
bath is removed in the formulation. The water in the quench bath plays a role in the
assembly of PS-b-PEG nanoparticles. Formulation consisting 75% antisolvent and 25%
organic solvent in mixer, quenched to 10% organic solvent were switched to 90%
antisolvent and 10% organic solvent in the mixer, without quench bath. These formulations
were modified to observe the effects of higher volume of antisolvent in the mixing chamber
and to retain 10% vol of organic solvent in the final solution. Overall, nanoparticle size
decrease in entry #6, #7, and #8 compare to entry #1, #2, and #3, respectively.
Size of nanoparticles can be controlled in FNP by two process variables: the percent core
(hydrophobic drug) of the formulation and the total mass concentration of solids
(hydrophobic drug and stabilizer) in the solvent stream.31 In entry #9 to #11, formulations
with increasing % drug (75.0%, 87.5% and 100.0%) were conducted to determine its size
range. The size of nanoparticles increased as % drug increase in the formulations. To
increase the size of nanoparticles and concentration of drug in the nanoparticle suspension,
the total mass concentration in the formulation were switched from 20 mg/mL to 40 mg/mL
in entry #12 and #13. 80.0% drug loading and 85.0% drug loading was selected for testing
because the desired size of nanoparticles is between 75.0% drug and 87.5% drug (167 nm
and 488 nm). The 85.0% drug loading generated nanoparticles that had a small increase in
size compare to 80.0% drug loading. Entry #12 generated PS-b-PEG nanoparticles, with
size at 165 nm and narrow size distribution (PDI 0.07) The stability of the 80.0% drug
loading nanoparticles was measured by DLS (Table 12). Size increase of “G-1”
nanoparticles were observed over different timepoints (0, 30, 60 minutes). The particle size
started at 185 nm and the size of the nanoparticle increase to 230 nm at 30-minute timepoint
which further increase to 320 nm at 60-minute timepoint. The size increase in the stability
study can explained by the phenomenon referred to as Ostwald ripening. Ostwald ripening
results from uncontrollable precipitation which leads to particle-size growth following
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stabilization.32 The 80% formulation was repeated to test for re-dispersity with various
cryoprotectant.
Table 11. Formulations conducted to generate ~200 to 300 nm “G-1” nanoparticles. a,b
Entry
Total Mass
% Drug
% PS-b-PEG
Quench
Size
PDI
Concentration
Bath
(nm)

#1 a

20 mg/mL

25.0%

75.0%

#2 a

20 mg/mL

50.0%

50.0%

#3 a

20 mg/mL

75.0%

25.0%

#4 a

20 mg/mL

100.0%

0.0%

#5 a

20 mg/mL

50.0%

50.0%

Yes
(6.0 mL)
Yes
(6.0 mL)
Yes
(6.0 mL)
Yes
(6.0 mL)
No

b

20 mg/mL

25.0%

75.0%

#7 b

20 mg/mL

50.0%

#8 b

20 mg/mL

#9 b

335

0.22

220

0.10

215

0.08

N/A

N/A

505

0.07

No

205

0.15

50.0%

No

130

0.07

75.0%

25.0%

No

160

0.07

20 mg/mL

75.0%

25.0%

No

170

0.07

#10 b

20 mg/mL

87.5%

12.5%

No

490

0.21

#11

b

20 mg/mL

100.0%

0.0%

No

785

0.14

#12

b

40 mg/mL

80.0%

20.0%

No

165

0.07

#13 b

40 mg/mL

85.0%

15.0%

No

225

0.09

#6

a

For entry #1-5, THF (1.0 mL) was used for the organic stream and HCl (3.0 mL, 10
mM) as an antisolvent.
b
For entry #6-13, THF (0.5 mL) was used for the organic stream and HCl (4.5 mL, 10
mM) as an antisolvent.
Table 12. Stability study of PS-b-PEG “G-1” nanoparticles (Formulation: 80% Drug +
20% PS-b-PEG in 0.5 mL THF (TMC = 40 mg/ml) and 4.5 mL of 10 mM HCl water).
Timepoint
Size (nm)
PDI
0 min
30 min
60 min

185
230
320

0.05
0.09
0.20

The nanoparticle suspension (Formulation: 80% Drug + 20% PS-b-PEG in 0.5 mL THF
(TMC = 40 mg/ml) and 4.5 mL of 10 mM HCl water) was lyophilized without and with 20
mg/mL of cryoprotectants (PEG, cyclodextrin, and trehalose) at the 30-minute timepoint
(Table 13). The lyophilized nanoparticles were tested for re-dispersity and analyzed
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through DLS. The size and PDI of the re-disperse nanoparticles with various cryoprotectant
are listed in Table 13. Cyclodextrin was the most effective cryoprotectant for
lyophilization of PS-b-PEG “G-1” nanoparticles. The PS-b-PEG “G-1” nanoparticles redispersed, with size at 325 nm, and narrow size distribution, (PDI 0.26). However,
substantial amount of aggregation was found in suspension. The formulation was repeated
and lyophilized with 40 mg/mL of cyclodextrin to improve re-dispersion. No aggregation
was found in the nanoparticle suspension. Moreover, the stability of the re-dispersed PSb-PEG “G-1” nanoparticles was measured by the DLS (Table 14). The size and size
distribution of the re-dispersed nanoparticles are listed in Table 14. The re-dispersed
nanoparticles were stable as size and PDI remain nearly unchanged.
Table 13. Re-dispersity test of PS-b-PEG “G-1” nanoparticles with different
cryoprotectants (Formulation: 80% Drug + 20% PS-b-PEG in 0.5 mL THF (TMC = 40
mg/ml) and 4.5 mL of 10 mM HCl water).
Cryoprotectants
Size (nm)
PDI
No Cryoprotectant
PEG
Cyclodextrin
Trehalose

N/A
460
325
N/A

N/A
0.53
0.26
N/A

Table 14. Stability study of re-dispersed PS-b-PEG “G-1” nanoparticles with
cyclodextrin (Formulation: 80% Drug + 20% PS-b-PEG in 0.5 mL THF (TMC = 40
mg/ml) and 4.5 mL of 10 mM HCl water).
Timepoint
Size (nm)
PDI
0 min
15 min
30 min
60 min

365
350
350
360

0.22
0.21
0.22
0.20

Increase Drug Loading (Wt%) Formulation
Nanoparticle formulations with higher drug loading is desired. At a higher drug loading,
less non active excipients are used to produce the same quantity of active pharmaceutical
ingredient (API) in the nanoparticle formulation and a lower number of nanoparticles need
to be manufactured to deliver the same dose of API.33 The objective is to generate “G-1”
nanoparticles with highest drug loading possible and good redispersity. In the original
formulation (80 mg/mL of “G-1” in 0.05 eq of NaOH with concentration of trehalose at 40
mg/mL), the drug loading (wt%) of the lyophilized “G-1” nanoparticle is 16.7%. In
addition, decreasing the amount of trehalose result in poorer redispersion of nanoparticles.
It is hypothesized that a critical concentration of trehalose is required to act as a
cryoprotectant. The removal of water can concentrate nanosuspension and thus allows
cryoprotectant to interact with the nanoparticles in suspension more effectively. By
concentrating nanoparticles before lyophilization, less cryoprotectant compared to drug
mass is needed.
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In order to increase drug weight % in the lyophilized nanoparticles, methods to increase
nanoparticle concentration was investigated. Tangential Flow Filtration (TFF) was used to
increase the concentration of nanoparticles by removing the water in the nanoparticle
suspension through filtration. “G-1” nanoparticles were formulated through the FNP
process via MIVM. The nanosuspension was concentrated by 5-fold (8 mg/mL into 40
mg/mL) through TFF. The concentration of “G-1” nanoparticles suspension before
filtration and after filtration was measured by UV-Vis. The concentration of “G-1”
nanoparticles suspension before filtration is 8 mg/mL. The concentration of “G-1”
nanoparticles suspension after filtration is 35 mg/mL. The concentrated nanosuspension
was tested against different concentration of trehalose in the lyophilization process. The
dried powder was re-dispersed into nanoparticles and analyzed through DLS (Table 15).
Particle size distribution of the re-dispersed nanoparticles are tabulated in Table 15.
Concentrated “G-1” nanoparticles with 80 mg/mL of trehalose (Increased Concentration
#2) re-disperse better than all other formulations. The size and the size distribution of the
re-disperse nanoparticles were the closest to the original formulation. The drug loading in
“Increased Concentration #2” formulation (30.5 wt% drug) is nearly double, compare to
the drug loading in the original formulation (16.7 wt% drug).
Table 15. Re-dispersity test of concentrated “G-1” nanoparticles (80 mg/mL of “G-1” in
0.05 eq of NaOH) with different concentration of cryoprotectant (trehalose)
Formulation
Nanoparticle
Trehalose
% Drug
Size
PDI
Concentration Concentration Loading (nm)
(mg/mL)
(mg/mL)
in Dried
Powder
Original
8
40
16.7%
88
0.21
Increased
Concentration #1
Increased
Concentration #2
Increased
Concentration #3
Increased
Concentration #4

35

40

46.6%

151

0.30

35

60

36.8%

185

0.41

35

80

30.5%

126

0.25

35

120

22.5%

137

0.31
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Conclusion
The oral bioavailability of “G-1” was improved through the formation of nanoparticles
through FNP. “G-1” formed ~80 nm particles which are self-stabilized without additional
use of steric copolymers. Nanoparticles can be formed with concentration of “G-1” as high
as 160 mg/mL. Lyophilization of “G-1” nanosuspensions with trehalose as cryoprotectant,
result in good redispersion of “G-1” nanoparticles. The dried powder of the final
formulations was sent to Genentech. The nanoparticles with trehalose show faster
dissolution rate than the nanoparticles formed in vivo from Genentech's spray dried
dispersion. Due to the rapid dissolution rate of free “G-1” powder, the differences in the
release kinetics of the free powder and the nanoparticles could not be discerned. Series of
formulations were conducted through the FNP process to generate ~300 nm “G-1”
nanoparticles. Nanoparticles with higher drug loading was achieved. Specifically, drug
loading of the original formulation was increased from 16.7% to 30.5%. The dried powder
of the final formulations (“G-1” nanoparticles with trehalose, ~300 nm “G-1” particles, and
30.5 wt% drug “G-1” nanoparticles) was sent to Genentech for better understanding in the
dissolution behavior of “G-1”, contributing to the knowledge of nanomedicine and
pharmaceutical sciences at Genentech.
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